A randomized double-blind trial including 73 patients with active RA further confirmed the therapeutic efficacy of anti-TNF treatment by measuring both laboratory and clinical parameters for the disease as well as monitoring tolerable adverse events in treated patients [42]. The gene discussed is TNF; the disease is rheumatoid arthritis.